← SynDRA
DANIRIXIN
SynDRA canonical compound SYN0037777 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | CXCR2 |
|---|
| Mechanism of action | CC chemokine receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- CXCR2 ANTAGONIST
- Interleukin-8 receptor B antagonist
- CC chemokine receptor antagonist
- CXCR2 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CX3CR1
- HRH2
- HTR1D
- HTR1E
- HTR2A
- HTR2B
- HTR2C
- HTR5A
- HTR6
- HTR7
- MBD4
- MPG
- MUTYH
- ADGRF1
- NEIL2
- OPRD1
- OPRK1
- OPRM1
- S1PR1
- SIGMAR1
- SLC6A3
- SLC6A4
- SMUG1
- TDG
- TSPO
- HTR1B
- HRH1
- ADRA1A
- HDAC6
- ADRA2A
- ADRA2B
- ADRA2C
- ADRB2
- ADRB3
- AGTR1
- APLNR
- C5AR1
- CCR7
- CHRM3
- CHRM4
Cross-references
Synonyms
- Danirixine
- Danirixina
- GSK1325756
- GSK-1325756B
- GSK1325756B
- UNII-R318PGH5VP
- R318PGH5VP
- Danirixin [USAN:INN]
- GSK 1325756
- Danirixin (USAN/INN)
- Danirixin(GSK1325756)
- GTPL8500
- SCHEMBL1198688
- CHEMBL3039531
- MolPort-044-561-791
- EX-A1178
- ZINC95627831
- AKOS030527036
- DB11922
- CS-5465
- 1-(4-Chloro-2-hydroxy-3-(((3S)-piperidine-3-sulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea
- HY-19768
- D10387
- (S)-1-(4-chloro-2-hydroxy-3-(piperidin-3-ylsulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea
- danirixinum
- RefChem:585166
- Danirixin (GSK1325756)
- MFCD27987922
- GSK-1325756
- DANIRIXIN [INN]
- DANIRIXIN [USAN]
- DANIRIXIN [WHO-DD]
- C19H21ClFN3O4S
- orb1302008
- SCHEMBL29815122
- Danirixin (GSK1325756)?
- GLXC-15693
- BDBM50633395
Look up DANIRIXIN in the interactive SynDRA portal →